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Abstract: Mitochondrial dysfunction and inflammation are widely accepted as key 
hallmarks of obesity-induced skeletal muscle insulin resistance. The aim of the present study 
was to evaluate the functional roles of an anti-inflammatory compound, celastrol, in 
mitochondrial dysfunction and insulin resistance induced by antimycin A (AMA) in human 
skeletal muscle cells. We found that celastrol treatment improved insulin-stimulated glucose 
uptake activity of AMA-treated cells, apparently via PI3K/Akt pathways, with significant 
enhancement of mitochondrial activities. Furthermore, celastrol prevented increased levels 
of cellular oxidative damage where the production of several pro-inflammatory cytokines in 
cultures cells was greatly reduced. Celastrol significantly increased protein phosphorylation 
of insulin signaling cascades with amplified expression of AMPK protein and attenuated 
NF-κB and PKC θ activation in human skeletal muscle treated with AMA. The improvement 
OPEN ACCESS
Molecules 2015, 20 8243 
 
 
of insulin signaling pathways by celastrol was also accompanied by augmented GLUT4 
protein expression. Taken together, these results suggest that celastrol may be advocated for 
use as a potential therapeutic molecule to protect against mitochondrial dysfunction-induced 
insulin resistance in human skeletal muscle cells. 
Keywords: celastrol; mitochondrial dysfunction; inflammation; human skeletal muscle; 
nuclear factor kappa B 
 
1. Introduction 
Over the past few decades, the global prevalence and incidence rate of type 2 diabetes mellitus has 
been escalating world-wide. It is currently estimated that over 350 million people world-wide suffer 
from this disease, and this figure is projected to rise to 600 million in 2035 [1,2]. The exact mechanism 
underpinning type 2 diabetes is still unknown, but oxidative stress, inflammation and mitochondrial 
dysfunction have been suggested to be among the central events contributing to the development of the 
disorder [3,4]. This postulation is perpetuated by a wealth of experimental and epidemiological studies 
showing that the impairment of mitochondrial functions in the skeletal muscle, liver and adipose tissues 
of both human and animal models are orchestrated by aberrant insulin signaling activities [3,5–8].  
To date, the precise link and interaction between mitochondrial dysfunction and insulin signaling 
pathways is still largely debated [3,9]. Substantial evidence from previous literature has pointed out that 
Complex I and III in the electron transport chain of mitochondria are major contributors to oxidative 
stress in diabetic patients [10,11]. Excessive accumulation of mitochondrial reactive oxygen species 
(ROS) production and chronic inflammation in peripheral tissues may lead to oxidative stress, thus 
leading to the oxidation of numerous intracellular components, including DNA, protein and membrane 
phospholipids. This process results in the activation of stress signaling pathways that participate in the 
development of insulin resistance. The activation of several oxidative stress-induced inflammation 
pathways, including c-Jun N-terminal kinases (JNK), protein kinase C (PKC), glycogen synthase kinase 
3 (GSK-3), nuclear factor-κB (NF-κB), and p38 mitogen-activated protein kinases (MAPK), have been 
shown to synergistically impair insulin signaling pathways. Notably, mounting evidence has shown that 
the central event connecting these cellular perturbations is severe disturbance of mitochondrial  
functions [3,9].  
Skeletal muscle is a major site of postprandial glucose disposal and the main target organ for various 
metabolic activities [12]. Elevated circulating free fatty acid-induced lipotoxicity and impairment of 
oxidative metabolism directly affect the insulin-stimulated glycogen synthesis in skeletal muscle [13]. 
High levels of intracellular C18:2 CoA, ceramides and diacylglycerols (DAGs) were associated with 
reduced mitochondrial functions and insulin signaling activity [3]. In this system, the defects in 
phosphorylation of tyrosine residue and amplified phosphorylation of serine residue in insulin receptor 
substrate-1 (IRS1) result in reduced IRS-1 associated PI3K activity with a concomitant increase of PKC θ 
activation [8]. The concerted action of these alterations in oxidative profiles of skeletal muscle leads to 
weakened insulin-stimulated glucose uptake via decreased glucose transporter-4 (GLUT4) translocation 
due to declined phosphorylation of AKT and its downstream effectors [14]. The defects in glucose 
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transport activity and diminished functions of phosphoinositide 3-kinase (PI3K) activity are among the 
direct consequences of cellular damage and oxidized biomolecules. Eventually, these perturbations lead 
to the activation of several inflammatory pathways including NF-κB and IκB kinase β (IKKβ) signaling 
and consequently enhance the expression of certain target genes responsible for interleukin-6 (IL-6), 
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production [15]. To a lesser extent, the 
chronic stimulation of these inflammatory pathways have been recognized as the “main culprits” that 
contribute to the progression of type 2 diabetes. Hence, further therapeutic interventions and prevention 
should be modulated towards targeting these regulatory pathways while boosting the metabolic pathways 
that promote enhanced cellular bioenergetics. 
Celastrol is an active ingredient of natural quinine-methide triterpenoid isolated from the plant family 
Celastraceae (Tripterygium wilfordii Hook F.), the traditional Chinese medicine also known as 
“Thunder God Vine.” This compound exhibits various biological activities including anti-oxidant,  
anti-inflammatory and anti-cancer properties [16]. In addition, celastrol was found able to inhibit  
NF-κB transcription factors and its downstream targets in various cell types without affecting the  
DNA-binding activity of activator protein 1 (AP-1) [17–19]. Recently, celastrol has shown to possess 
anti-diabetic effects on diabetic nephropathy and improve whole-body insulin resistance [20]. The 
authors observed that in vivo administration of celastrol for 2 months in six-week-old male diabetic db/db 
mice (C57BLKS/J-leprdb/leprdb) improved insulin resistance, oxidative stress and glycemic control with 
substantial restoration of renal functional and diabetes-induced structural changes. In other cell types, 
celastrol was shown to exhibit cytoprotective properties in vascular smooth muscle cells (VSMCs) and 
myocardioblast via heme oxygenase-1 (HO-1) induction [21,22]. However, the effects of celastrol on 
the amelioration of mitochondrial dysfunction-induced oxidative damage in skeletal muscle cells with 
insulin resistance are not currently available. 
We have previously reported that celastrol improved the oxidative metabolism of adipocytes with 
mitochondrial dysfunction via inhibition of NF-κB signaling pathways [23]. On the basis of these 
observations, it is of interest to investigate the effects of celastrol on mitochondrial dysfunction and 
insulin resistance in human skeletal muscle-derived myoblast. In this context, the present study 
established an in vitro model of mitochondrial dysfunction and insulin resistance in human skeletal 
muscle induced by antimycin A (AMA), a mitochondrial Complex III inhibitor. The results showed that 
celastrol can protect the cells from AMA-induced insulin resistance and mitochondria dysfunction. This 
is achieved via significant improvement in glucose uptake activity, mitochondria functions and oxidative 
metabolism, enhanced insulin signaling cascade pathways, and its downstream effectors. 
2. Results and Discussion  
2.1. Effects of AMA and Celastrol Treatment on Cell Viability (Dose and Time-Dependent)  
Firstly, dose and time-dependent MTT assays were performed to determine the effect of AMA and 
celastrol on viability of skeletal muscle cells. After serum starvation, cells were treated with a series of 
concentrations (15, 30, 60, 120 µM and nM for both AMA and celastrol, respectively) for 24 h. As 
shown in Figure 1A,B, both AMA and celastrol reduced cell viability in a dose-dependent manner. The 
optimal concentration of AMA that did not significantly inhibit cell viability was 30 µM. The result also 
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showed that celastrol at the doses of 30, 60 and 120 nM significantly decreased cell viability by 35%, 
46% and 49%, respectively. Therefore, celastrol at a dose of 15 nM was chosen for all subsequent 
experiments. Moreover, we also performed the time-dependent evaluation (12, 24, 36 and 48 h) for cells 
treated with the selected single concentrations of 30 µM AMA and 15 nM celastrol (Figure 1C). There 
was no significant effect on cell viability after AMA and celastrol treatment for 48 h. A number of studies 
reported that the optimal doses of celastrol that did not significantly inhibit cell viability were found to 
be in the nano-molar range, with an incubation time of no more than 24 h [22,24,25]. Furthermore, 
another group observed that continuous exposure of celastrol at sub-micromolar concentrations is linked 
to reduced cellular viability and proliferation [26]. Consistently, our result showed that an incubation of 
15 nM celastrol in human skeletal muscle cells for 48 h did not affect cell viability. 
As shown in Figure 1D, human skeletal muscle cell treated with low dose DMSO as control exhibits 
a typical epithelial phenotype with small polygonal shapes. Co-incubation with AMA treatment alone 
(Figure 1E) induces enlargement of cytoplasm with a tight arrangement linking the cells. However, when 
exposed to 15 nM celastrol in AMA-treated cells, cells acquired a spindle-shaped structure with variable 
sizes (Figure 1F). To avoid other confounding factors, cells were treated with celastrol only. As depicted 
in Figure 1G, celastrol treatment alone induces morphological changes in the cells that are somewhat 




Figure 1. Cont. 







Figure 1. MTT cell viability assay on human skeletal muscle after AMA and celastrol 
treatment. Cell viability of AMA (A) and celastrol (B) was performed in a dose-dependent 
manner. The time-course evaluation of the optimal dose for AMA (30 µM) and celastrol 
(15 nM) was determined (C). Figures of the untreated cells (DMSO) (D), 30 µM  
AMA-treated cells (E), 15 nM celastrol-treated cell (F) and AMA-treated cells with  
15 nM celastrol treatment (G) were taken at 40X magnification using fluorescence 
inverted microscope (Carl Zeiss, Göttingen, Germany). Figures represent one of three 
independent experiments. * p < 0.05 and ** p < 0.01 vs. untreated control. 
2.2. Celastrol Increased Glucose Uptake in Insulin-Resistant Myotubes through the PI3K/Akt Pathway 
The impairments in glucose uptake and utilization are among the key events associated with 
mitochondrial dysfunction and insulin resistance [23,27]. We first investigated the effects of AMA alone 
on glucose uptake activity in human skeletal muscle using a 3H-2-DG uptake assay. As shown in Figure 2, 
cells under normal insulin-stimulated conditions (100 nM, 30 min) exhibited marked increase (50%,  
p < 0.05) in glucose uptake activity, compared to the basal level. However, AMA at a concentration of 
30 µM was found to significantly decrease the basal (38%, p < 0.05) and insulin-stimulated glucose 
uptake activity (−78%, p < 0.01) compared to insulin-stimulated cells. This is in line with earlier findings 
that AMA treatment leads to impairment of glucose uptake activity in the cell [8]. Therefore, AMA 
treatment was used in the following experiments to induce mitochondrial dysfunction-induced insulin 
resistance in human skeletal muscle cells. 
An evaluation of celastrol treatment alone on glucose uptake activity in human skeletal muscle was 
conducted. We found no significant changes in the basal glucose uptake activity for cells treated with 
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celastrol. Conversely, with insulin stimulation, celastrol significantly enhanced insulin-stimulated 
glucose uptake in AMA-treated cells, with an 86% (p < 0.05) increase in glucose uptake activity. These 
results may indicate that celastrol alone can be used as an insulin sensitizing agent for enhancement of 
glucose uptake activity in human skeletal muscle cells. Wortmannin, a potent PI3K-specific inhibitor, 
was utilized in the study to examine the mechanistic action of celastrol in regulating glucose uptake 
activity. Increasing evidence indicates that PI3K/Akt pathways are the key regulator of glucose 
metabolism and intracellular signaling activities relative to mitochondrial functions [28,29].  
Co-incubation with wortmannin in human skeletal muscle diminished the glucose uptake activity in 
basal and insulin-stimulated conditions by −38% (p < 0.05) and −68% (p < 0.01), respectively, compared 
to untreated group. 
Then, the effect of celastrol on AMA-treated cells was investigated. Co-treatment of celastrol on 
human skeletal muscle cells with mitochondrial dysfunction was investigated. The result showed that 
treatment with 15 nM celastrol on cells in the event of insulin stimulation significantly enhanced glucose 
uptake activity by +63% (p < 0.05) compared to AMA-treated cells. However, no significant difference 
was observed after celastrol treatment of AMA-treated cells at the basal level. Consequently, to evaluate 
whether the PI3K/Akt pathway is linked to celastrol-mediated improvements in glucose uptake activity, 
cells were pre-incubated with 100 nM wortmannin for 30 min before celastrol incubation. Co-treatment 
with wortmannin in insulin-resistant myotubes significantly diminished celastrol-induced insulin 
stimulation (−61%, p < 0.05) and basal (−18%, p < 0.05) glucose uptake activity (Figure 3B). These 
results indicated that celastrol treatment on skeletal muscle insulin resistance induced by AMA is 
modulated via PI3K/Akt pathways. 
 
Figure 2. The mechanistic effects of AMA and celastrol treatment on the glucose uptake 
activity in skeletal muscle cells. Co-treatment with celastrol on skeletal muscle cells with 
mitochondrial dysfunction for 48 h improved insulin-mediated glucose uptake activity. 
However, wortmannin blocked this beneficial effects of celastrol on AMA-treated cells.  
# p< 0.05 vs. basal rate; + p < 0.05 vs. AMA-treated cells. 
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2.3. Celastrol Improves Mitochondrial Activity and Energy Production in AMA-Induced  
Insulin-Resistant Human Skeletal Muscle Cells  
The localization of the binding activity for inflammatory signaling NF-κB subunits p50 and p65 along 
with IκB were found in mitochondria, suggesting the involvement of this pathway in regulating 
mitochondrial activities [30]. Our earlier study demonstrated that NF-κB inhibition in adipocytes with 
insulin resistance led to the improvement of mitochondrial functions [23]. As celastrol has been reported 
to exhibit potent NF-κB inhibitors, we examined the mitochondrial functions of skeletal muscle cells 
after incubation with AMA and celastrol.  
The energy production of the energetic tissues, including skeletal muscle, heart and liver, are mainly 
regulated by mitochondria in the form of chemical energy, known as adenosine triphosphate (ATP). In 
the present study (Figure 3A), insulin-treated cells exhibited with higher intracellular ATP 
concentrations (+200%, p < 0.01) than the basal group (untreated). AMA caused significant decrease in 
the intracellular ATP concentrations of both basal (−44%, p < 0.05) and insulin-stimulated (−70%, p < 0.01) 
cells. However, exposure to celastrol abolished this effect by elevating the intracellular ATP 
concentration levels of skeletal muscle cells in the absence (+46%, p < 0.05) and presence (+65%, p < 0.05) 
of insulin. Interestingly, treatment of human skeletal muscle with celastrol alone enhanced intracellular 
ATP content by +38% (p < 0.01) at the basal level while no significant effect was observed on the 
insulin-stimulated condition. Mitochondrial membrane integrity is one of the key indicators in 
determining normal cell function. Therefore, we examined whether celastrol affects mitochondrial 
membrane integrity (MMP). In brief, we measured the MMP using JC-1, a cationic dye that accumulates 
in mitochondria, and correlated it with the function of proton gradient. As depicted in Figure 3B, AMA 
treatment for 48 h decreased the MMP level by 58% (p < 0.01) relative to untreated cells. However, 
celastrol effectively recovered this detrimental effect of AMA by augmenting the level of MMP with a 
42% increase (p < 0.05) compared to AMA-treated cells. Exposure to celastrol alone in cells revealed 
no significant changes to MMP levels compared to control (untreated). 
To examine the association between mitochondrial dysfunction and ROS, the measurement of 
mitochondrial superoxide production was performed using a DCFDA assay kit. AMA caused a 
significant rise in ROS production (+125%, p < 0.05) while celastrol abolished this effect with an 84% 
(p < 0.05) decrease in mitochondrial superoxide production in human myotubes after 48 h (Figure 3C). 
In contrast, the previous report [22] showed that rapid treatment of celastrol on cardiomyoblast 
stimulates ROS production in 5–60 min. The difference in these observations is due to the different time 
point in measuring ROS production. In addition, we observed that celastrol treatment alone for 48 h 
revealed no changes to mitochondrial superoxide production levels relative to control.  
Citrate synthase activity is commonly used as a marker of aerobic capacity and mitochondrial density 
in numerous energetic tissues such as skeletal muscle, liver and brain [31]. Following AMA treatment, 
we observed the reduced level (−65%, p < 0.01) of citrate synthase activity, which confirmed that  
AMA-induced mitochondrial dysfunction affects mitochondrial enzyme activity. Upon addition of 
celastrol, citrate synthase activity was significantly augmented (+53%, p < 0.05), as compared to  
AMA-treated cells (Figure 3D). A single treatment of human skeletal muscle cells with celastrol does 
not affect citrate synthase activity compared to control. 





Figure 3. AMA and celastrol treatment of mitochondrial functions of skeletal muscle cells. 
After incubation, cells were assayed to measure intracellular ATP concentration (A), 
mitochondrial membrane potential (B), mitochondrial superoxide production (C) and citrate 
synthase activity (D). Basal and insulin-stimulated levels were shown. Basal rate refers to 
the rate of glucose transport in the absence of insulin. * p < 0.05 and ** p < 0.01 vs. untreated 
control; # p < 0.05 and ## p < 0.01 vs. basal rate; + p < 0.05 vs. AMA-treated cells. 
2.4. Celastrol Attenuates Oxidative Stress in AMA-Treated Human Skeletal Muscle Cells 
There is growing evidence of the interplay relationship between oxidative stress and mitochondrial 
dysfunction in the progression of skeletal muscle insulin resistance [3,32]. Here, we examined the effects 
of celastrol on oxidative stress markers (including 8-OHdG DNA, protein carbonylation and lipid 
peroxidation) of AMA-treated human skeletal muscle cells. As depicted in Figure 4A–C, AMA 
significantly augmented the level of 8-OHdG DNA (+300%, p < 0.01), protein carbonyls (+160%, p < 0.01) 
and lipid peroxidation (+190%, p < 0.01) in human myotubes compared to untreated cells. Notably, all 
these deleterious impacts can be reversed by celastrol treatment. Relative to conditioned control, 
celastrol treatment alone showed no significant impact on the following parameters of the oxidative 
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stress level, except for lipid peroxidation, where celastrol significantly reduced the MDA level by −28% 
(p < 0.05). 
A B C 
Figure 4. Effects of AMA and celastrol on the oxidative properties of human skeletal 
muscle. The quantification of 8-OHdG DNA (A), protein carbonyls (B) and lipid 
peroxidation levels (C) was determined after 30 µM AMA treatment with or without addition 
of 15 nM celastrol and celastrol treatment alone. Values are normalized against standard 
curves generated according to standard protocol provided by manufacturers. * p < 0.05 and 
** p < 0.01 vs. untreated control; + p < 0.05 and ++ p < 0.01 vs. AMA-treated cells. 
2.5. Celastrol Affects Mitochondrial Dynamics via Mitochondrial Fusion and Fission in AMA-Treated 
Skeletal Muscle Cells 
To further investigate the effects of AMA and celastrol on mitochondrial functions, we also measured 
the celastrol treatment of the expressions of mitochondrial fusion (mfn1 and mfn2) and fission (drp1) 
proteins. The result showed that AMA exposure to human myotubes upregulated the expression of mf1 
and mfn2 proteins by 91% (p < 0.01) and 40% (p < 0.05), respectively. However, the presence of 
celastrol abrogated this aberrant effect by reducing the expression of mfn1 (−69%, p < 0.05) and mfn2 
(−43%, p < 0.05) in human myotubes after 48 h of AMA treatment compared to control group. In line 
with this, drp1 protein level was partly reduced (−28%, p < 0.05) after AMA treatment but was amplified 
(+68%, p < 0.01) after pre-incubation with celastrol. (No significant changes were observed in the 
relative expression of mfn1, mfn2 and drp1 protein levels after treatment with 15 nM celastrol alone 
(Figure 5A–D). 





B C D 
Figure 5. Effects of AMA and celastrol treatments on mitochondrial fusion and fission of 
human myotubes. Representative images of western blot analysis (A) on the relative 
expression of (B) mfn1, (C) mfn2 and (D) drp1 proteins were quantified with the 
corresponding antibodies using a densitometer. β-actin was used as loading control. Protein 
levels calculated by densitometry were normalized relative to β-actin signals. * p < 0.05 and 
** p < 0.01 vs. untreated control; + p < 0.05 and ++ p < 0.01 vs. AMA-treated cells. 
2.6. Effect of Celastrol on the Production of Pro-Inflammatory Cytokines IL-6, TNF-α and IL-1β in 
AMA-Induced Mitochondrial Dysfunction Human Skeletal Muscle Cells 
To examine whether the regulatory function of celastrol was associated with the activities of 
inflammatory cytokines, we measured the levels of IL-6, TNF-α and IL-1β using an ELISA-based assay. 
Interestingly, we found that AMA-treated cells exhibited augmented production of IL-6 (+280%, p < 0.01), 
TNF-α (+313%, p < 0.01) and IL-1β (+410%, p < 0.01) relative control cells. Upon co-incubation with 
celastrol, the amplified levels of IL-6, TNF-α and IL-1β were diminished by −157% (p < 0.05), −295% 
(p < 0.01) and −198% (p < 0.05) compared to AMA-treated cells as shown in Figure 6A–C. As a 
conditioned control, we co-incubated celastrol alone in human skeletal muscle cells. The result revealed 
that celastrol caused significant reduction (29%, p < 0.05) in TNF-α levels in normal human skeletal 
muscle cells while no significant changes were observed in the production of IL-6 and IL-1β.  
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A B C 
Figure 6. Effects of AMA and celastrol on the production of pro-inflammatory cytokines 
with regard to mitochondrial-induced insulin resistance in human myotubes. Cells were 
incubated for 48 h with DMSO (control), AMA, celastrol-AMA and celastrol only. The 
quantification of IL-6 (A), TNF-α (B) and IL-1β (C) was determined as briefly described in 
materials and methods. Values are normalized against standard curves generated according 
to standard protocols provided by manufacturers. * p < 0.05 and ** p < 0.01 vs. untreated 
control; + p < 0.05 and ++ p < 0.01 vs. AMA-treated cells. 
2.7. Effect of AMA and Celastrol on NF-κB and IκBα Expression Protein Activity 
Next, we quantified the expression level of NF-κB (Ser-536) and IκBα (Ser-32) protein activity in 
human skeletal muscle cells after AMA treatment with or without celastrol. AMA significantly  
up-regulated NF-κB (+54%, p < 0.05) and IκBα (+69%, p < 0.05) protein expression activity  
(Figure 7A–C). Addition of 15 nM celastrol to these incubations attenuated the enhanced NF-κB 
phosphorylation (−56%, p < 0.05) and significantly blocked IκBα activity (−52%, p < 0.05) by inhibiting 
Ser-32 phosphorylation. Incubation with celastrol in normal cells exhibited no significant effect on the 
relative expression of NF-κB and IκBα protein activity even though celastrol has been reported to 
severely inhibit the expression of these proteins. This may suggest that the mechanistic effects of  
NF-κB inhibition in human skeletal muscle cells are selectively modulated in the event of mitochondrial 
dysfunction and metabolic stress. 
A 
Figure 7. Cont. 





Figure 7. AMA treatment of human myotubes in the absence and presence of celastrol. Cells 
were grown in 6-well plates and treated with AMA and celastrol for 48 h. The representative 
images of western blot analysis (A) of the relative expression level of NF-κB (B) and IκBα 
(C) activity was measured and quantified. β-actin was used as a loading control. Protein 
levels calculated by densitometry were normalized relative to β-actin signals. * p < 0.05 vs. 
untreated control; + p < 0.05 vs. AMA-treated cells. 
2.8. Effects of Celastrol on Protein Expression of Insulin Signaling Pathways and GLUT4 in  
AMA-Treated Human Skeletal Muscle Cells 
A number of downstream proteins targets of insulin signaling pathways including IRS1, Akt and 
AS160 have been postulated to play significant roles in insulin-stimulated glucose uptake [3,27]. In the 
present study, we examined the effects of celastrol on these downstream protein targets of human skeletal 
muscle cells treated with AMA. At 100 nM insulin stimulation, AMA-treated cells presented a 
significant reduced protein phosphorylation (all p < 0.05) of IRS1 (Tyr612) (−70%, Figure 8C), Akt 
(Ser473) (−74%, Figure 8D) and AS160 (Thr642) (−56% Figure 8E), compared to the insulin-treated 
control group. These AMA-induced reductions can be reversed by the addition of celastrol and resulted 
in significant increases (all p < 0.05) in protein phosphorylation of IRS1 (+45%), Akt (+63%) and  
AS160 (+45%).  
To corroborate with abovementioned analysis, we further assessed the effect of AMA and celastrol 
on the relative expression of glucose transporter protein, GLUT4 relative to insulin stimulation  
(Figure 8B). Addition of AMA into the cultured human myotubes resulted to a significant reduction of 
GLUT4 protein expression with 66% (p < 0.01) compared to control group. Celastrol improved this 
impairment by elevating the expression of GLUT4 protein by 46% relative to AMA-treated human 
(Figure 8B,F). These data are consistent with the celastrol-induced increase in glucose uptake via 
significant enhancement of intracellular insulin signaling pathways. 








Figure 8. Cont. 




Figure 8. Effects of AMA and celastrol treatment on insulin signaling pathways and glucose 
transporters (GLUT4) of human myotubes. Cells were treated with AMA (30 µM) for  
48 h before incubation with celastrol (15 nM). β-actin was used as an internal protein loading 
control. Protein levels for each corresponding antibody obtained from densitometry were 
normalized to the β-actin signal (A–F). * p < 0.05 and ** p < 0.01 vs. untreated control;  
# p< 0.05 vs. basal rate; + p < 0.05 and ++ p < 0.01 vs. AMA-treated cells. 
2.9. Celastrol-Regulated pAMPK Expression and Inhibition of PKC θ in AMA-Treated Skeletal  
Muscle Cells 
The dysregulation of certain intracellular signaling pathways have been linked to the development of 
mitochondrial dysfunction and insulin resistance in a variety of insulin target tissues [3]. A reduced 
AMPK phosphorylation in skeletal muscle is also recognized as one of the key features of unhealthy 
cells with impaired lipid and glucose metabolism [33]. Long-term activation of PKC θ transcription 
factors is among the pivotal mechanisms involved in the event of skeletal muscle insulin resistance [34]. 
It would be interesting, therefore, to explore whether the ameliorative properties of celastrol affect these 
intracellular signaling pathways. Our study found that, compared with vehicle (control), AMA 
significantly diminished the level of phosphorylated AMPK (Thr-172) in the absence (−20%, p < 0.05) 
and presence (−70%, p < 0.01) of insulin. However, co-incubation with celastrol led to significant 
elevation of AMPK expression of AMA-treated cells (Figure 9A–B). As the stimulation of NF-κB 
signaling activity is correlated with the activation of PKC θ, this prompted us to explore the correlative 
links between the roles of celastrol and regulation of PKC θ pathways. AMA exposure on human 
myotubes caused an increased phosphorylation expression (+51%, p < 0.05) of PKC θ (Ser-643/676) 
protein activity compared to untreated cells. Nevertheless, celastrol suppressed the effects of an  
AMA-induced increase of PKC θ activity by reducing the expression of PKC θ protein phosphorylation 
at the basal and insulin stimulation by −121% (p < 0.01) and −102% (p < 0.01), respectively, compared 
to AMA-treated cells. (Figure 9A–C). 







Figure 9. Effects of AMA and celastrol treatments on the protein expression of AMPK 
(Thr172) and PKC θ (Ser643/676) in human skeletal muscle-derived myoblast. Cells were 
cultured in media containing 30 µM AMA in the absence and presence of 15 nM celastrol 
for 48 h. Thereafter, cell lysates were subjected to western blot analysis (A). The percentage 
of specific and total protein phosphorylation was calculated to determine the relative level 
of exact amino acid residue phosphorylation (A–C). β-actin was used as internal protein 
loading control. Protein levels for each corresponding antibody obtained from densitometry 
were normalized to the β-actin signal. * p < 0.05 and ** p < 0.01 vs. untreated control;  
+ p < 0.05 and ++ p < 0.01 vs. AMA-treated cells. 
2.10. Discussion  
The evidence implicating the association between oxidative stress and inflammation in a number of 
peripheral tissues is correlative. However, the establishment of other in vitro phenotypes such as 
mitochondrial dysfunction-associated inflammation in skeletal muscle with insulin resistance has not 
been largely demonstrated. Correspondingly, there have been limited studies on the roles of 
inflammatory signaling pathways in the regulation of mitochondrial function. To our knowledge, the 
present study provides the first evidence in examining whether celastrol, a potent NF-κB inhibitor, 
Molecules 2015, 20 8257 
 
 
protects against mitochondrial dysfunction-induced insulin resistance in human skeletal muscle-derived 
myoblast. The current study supports the hypothesis that celastrol treatment attenuates the aberrant 
characteristics of skeletal muscle insulin resistance induced by deteriorated mitochondrial functions. The 
key findings of this study include the ability of celastrol to modulate intracellular insulin signaling 
pathways and its downstream effectors in the event of mitochondrial dysfunction in human skeletal 
muscle cells.  
Insulin-stimulated glucose uptake assay is considered a “gold standard” in evaluating the degree of 
insulin resistance at the cellular level. It is generally believed that PI3K is the central regulatory axis 
pathway in intracellular insulin signaling cascades [35]. The activation of downstream effectors of IRS1 
is predominantly dependent on the subsequent activation of the insulin receptor β subunit that leads to 
the stimulation of serine phosphorylation downstream of PI3K, known as Akt. The phosphorylation of 
Akt binding sites can promote GLUT4 translocation to cell membrane. Insulin signaling activities are 
known to be affected by mitochondrial dysfunction, oxidative stress and subsequent defects in other 
metabolic processes such as ATP contents, mitochondrial membrane potential, citrate synthase activity 
and ROS production [3,23]. This is supported by the fact that reduced oxidative phosphorylation rate, 
lower mitochondrial content and changes in mitochondrial dynamics of numerous peripheral tissues are 
related to the development of insulin resistance [36,37]. Moreover, it has been shown that impaired 
mitochondrial activities are linked to a disturbance in the relative function of mitochondrial  
dynamics [37,38]. This evidence implies that improvement of mitochondrial function may result in the 
improvement of peripheral and systemic insulin sensitivity as a whole. It was presumed that 
multiplication in ROS production serves to exacerbate oxidative stress mediated by augmented 
expression NF-κB binding activity [39]. Excess accumulation of pro-inflammatory cytokines in the 
event of mitochondrial dysfunction in normal human chondrocytes is linked to the overproduction of 
ROS and activation of NF-κB activities [40]. An integrative approach utilizing in vitro and in vivo studies 
discovered that high level of inflammatory gene expression due to enhanced binding sites of NF-κB 
activity was associated with mitochondrial H2O2 production-induced mitochondrial dysfunction [41,42]. 
The defects in mitochondrial respiration function with reduced ATP content in high-fat diet  
(HFD)-induced obese mice was accompanied by reduced expression of mfn1 and mfn2, while drp1 
protein was significantly amplified when compared to the control group [43]. Additionally, it has been 
shown that the regulation of the Akt-mTOR-NF-κB signaling pathway in cardiomyocytes in vitro and  
in vivo is modulated via up-regulated mitochondrial fusions in the presence of insulin stimulation [28]. 
In this study, celastrol exhibits attributive properties via improvement of mitochondrial functions 
together with attenuated oxidative stress in AMA-treated skeletal muscle. This data suggests that 
celastrol may have potent effects on the improvement of mitochondrial functions in regards to the 
progression of insulin resistance in human skeletal muscle cells.  
High levels of pro-inflammatory cytokines IL-6, TNF-α and IL-1β has been implicated with the 
progression of type 2 diabetes and glucose intolerance [44]. Here, we found that celastrol significantly 
abrogated the overwhelmed production of pro-inflammatory cytokines IL-6, TNF-α and IL-1β in  
AMA-treated cells. This observation is supported by previous reports showing that NF-κB transcription 
factors are responsible for mediating the expression of genes involved in the production of  
pro-inflammatory cytokines, chemokines and adhesion molecules [45]. As a potent inhibitor of NF-κB 
activity, celastrol may have had its effects on these pro-inflammatory genes and rescued human 
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myotubes from an insulin-resistant state. The present study suggests that the complex mechanism of 
celastrol could be regulated via synergistic enhancement of mitochondrial functions affecting oxidative 
metabolism and inflammatory response of the human skeletal muscle cells. The associative mechanism 
linking the development of mitochondrial dysfunction and inflammation is gaining attention [3,15].  
NF-κB signaling activities have been proposed as one of the prominent pathways leading to the 
activation of inflammatory response in various cell types. Celastrol is a well-known potent inhibitor of 
NF-kB activation via in vitro and in vivo analyses [17,19,20,46–49]. Our result is consistent with earlier 
findings on the role of celastrol as a potent inhibitor of NF-κB and its nuclear translocation activity in a 
variety of cell types. 
Insulin is an anabolic hormone that is released by the pancreas and serves to facilitate glucose uptake 
activity and glycogen storage in skeletal muscle. Excessive accumulation of intermediate lipid 
metabolites including DAG and ceramides activates serine kinase PKC θ and NF-κB transcription 
factors, thus promoting the inhibition of tyrosine phosphorylation via IRS1, AKT substrate of 160 kDa 
(AS160) and PI3K-related pathways. This process results in the diminished function of insulin signaling 
pathways, lessening the translocation of GLUT4 into the cell surface [50]. Oxidative stress and insulin 
resistance are closely associated with inflammation, evoking an inflammatory response via NF-κB and 
MAPK-mediated signaling [51]. The upsurge of ROS generation activates numerous inflammatory 
signaling pathways such as JNK and PKC and directly alters the inflammatory response in the peripheral 
tissues. The activation of intracellular signaling pathways by high levels of long-chain fatty acids and 
pro-inflammatory mediators enables the dissociation of NF-κB from inhibitors of IκB proteins for its 
translocation to the nucleus [52]. The subsequent activation of NF-κB boosts the transcription factors of 
various gene encoding inflammatory mediators such as IL-6 and TNF-α [53]. Elevated levels of these 
pro-inflammatory cytokines with boosted NF-κB activity may further mediate the activation and 
phosphorylation of intracellular signaling molecule JNK in skeletal muscle via inhibition of AS160 
phosphorylation [54]. The excessive activation of serine phosphorylation of IRS1 by phosphorylated 
JNK (p-JNK) leads to the impairment of insulin signal transduction [55–57]. Prolonged activation of 
these inflammatory pathways results in the development of skeletal muscle insulin resistance [45]. In 
view of the involvement of mitochondrial dysfunction and oxidative stress-induced inflammation, the 
suppression of ROS production and inhibition of NF-κB-dependent inflammatory responses by celastrol 
in human skeletal muscle cells should be responsible for its beneficial regulation of IRS1-Akt-AS160 
protein phosphorylation pathways. It is now becoming clear that celastrol produces an improvement to 
mitochondrial function of the human skeletal muscle cells with insulin resistance via enhanced 
intracellular insulin signaling pathways. 
In the event of oxidative stress and mitochondrial dysfunction, previous studies showed that Complex 
I and III are the major sources of free-radical production [58]. Subsequently, this would result in the 
activation of serine/threonine phosphorylation on IRS-1, which in turn lead to the attenuation of IRS1 to 
activate PI3K and Akt [59]. Severe impairment in intracellular insulin signaling cascades may inherently 
inhibit translocation of GLUT4 to cell surface, so glucose uptake is reduced. The relative translocation 
of glucose transporters to the plasma membrane in the skeletal muscle has been recognized as one of 
key events in maintaining glucose homeostasis. It has been shown that the expression of GLUT4 protein 
level in skeletal muscle of type 2 diabetes subjects were reduced [60–62]. In the context of inflammatory 
signaling response, the participation of NF-κB signaling pathways in regulating GLUT4 mRNA 
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repression of skeletal muscle was first documented earlier [63]. In their study, there was an elevation of 
GLUT4 mRNA level in parallel to the reduced NF-κB activity in skeletal muscle of the fasted rats 
without insulin and glucose stimulation. Our finding substantiated the underlying mechanism on the 
effects of celastrol on the relative expression of GLUT4 protein and intracellular insulin signaling 
cascade events. 
AMPK, a fuel sensing enzyme in present in numerous cell types, has been reported to exhibit a wide 
range of functions in regulating lipid and glucose metabolism in peripheral tissues. Pharmacological 
activation of this sensor promote the enhancement of fatty acid oxidation, mitochondrial biogenesis, 
GLUT4 translocation and insulin sensitivity [64,65]. Prolonged modification of cellular redox status, 
mitochondrial dysfunction and metabolic reprogramming are thought to be modulated via  
AMPK-mediated signaling pathways. It has been shown that AMPK activation can down-regulate the 
antagonistic effects of elevated pro-inflammatory cytokines IL-6 and IL-8 in human adipose tissue and 
skeletal muscle cells [66]. In view of that, one study showed that the expression level of NF-κB-p65 
DNA-binding activity in myocytes from obese type 2 diabetes subjects was down-regulated following 
activation of AMPK by A769662 (activator of AMPK), but no effects on the insulin sensitivity of the 
cells were observed [67]. On the other hand, Barma and his colleagues found that the upsurge in the 
relative expression of NF-κB genes and proteins was mediated by phospho-PKC in insulin-resistant 
skeletal muscle cells [68]. High levels of NF-κB expression activity forced the cells to become insulin 
resistant. It has been observed that the transfer of phosphate group from PKC to NF-κB occurred in 
skeletal muscle cell free systems incubated with palmitate. Long chain fatty acids including palmitate 
have been shown to affect mitochondrial activity, insulin-stimulated glucose uptake and insulin signaling 
cascade events [3]. The present investigation indicates celastrol may have some attributive effects in 
transducing the level of the expression level of these proteins, thus preventing the development of 
mitochondrial dysfunction-induced insulin resistance in human skeletal muscle cells. 
 
Figure 10. Schematic representation of the mechanistic action of celastrol on mitochondrial 
dysfunction-induced insulin resistance in human skeletal muscle cells. 
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It is known that celastrol can act as potent inhibitor of NF-κB signaling activities in various cell  
types [17,21,23,69]. In addition to its previous metabolic effects, the present investigation revealed that 
these unique characteristics of celastrol may have profound effects on a number of downstream pathways 
involving insulin sensitivity and glucose homeostasis of human skeletal muscle cells treated with AMA. 
As shown in Figure 10, we provide the first evidence that the mechanism underlying celastrol treatment 
in the event of mitochondrial dysfunction-induced insulin resistance is largely mediated through 
synergistic enhancement of mitochondrial functions and activation of anti-inflammatory pathways, 
leading to the metabolic improvement of intracellular signaling pathways in skeletal muscle insulin 
resistance. Nevertheless, the exact mechanism linking these metabolic improvements from celastrol in 
whole-body organisms against mitochondrial dysfunction-induced insulin resistance remains unclear, 
suggesting further investigation in vivo will be necessary to unravel these complex mechanisms. 
3. Experimental Section  
3.1. Cell Culture 
Human skeletal myoblasts (SKM102512A) were purchased from Zenbio Inc. and maintained at  
sub-confluence in skeletal muscle cell growth medium (SKM-M) (Zenbio Inc., Durham, NC, USA). The 
medium contains 1.0 g/L D-glucose Dulbecco’s modified Engle’s medium (DMEM) supplemented with 
fetal bovine serum, bovine serum albumin, fetuin, human insulin and antibiotics (penicillin, streptomycin 
and amphotericin B). The growth media were replaced every two days. Cells were incubated at 37 °C in 
a humidified atmosphere of 5% CO2. Cells at passages 3–9 were used in all experiments of the current 
study. The 80%–90% confluent myoblasts were then washed with phosphate buffer saline (PBS), and 
differentiated to myotubes in skeletal muscle cell differentiation medium (SKM-D) (Zenbio Inc., 
Durham, NC, USA) with 10% of horse serum and antibiotics. Fresh differentiation media were added 
every 2–3 days. Myoblast were fused to form myotubes after 6 days of differentiation process, as 
presented by the appearance of elongated and multinucleated cells. The assays were performed 
accordingly on differentiated myotubes after seeding. The details of the donor and copy of certificate 
analysis provided by Zenbio Inc. is included in Supplementary 1. 
3.2. AMA and Celastrol Treatment 
The induction of mitochondrial dysfunction and insulin resistance by AMA (Sigma, St. Louis, MO, 
USA) in human myotubes was performed as previously reported [70]. Cells were serum-starved for 18 h 
prior to the treatment at 37 °C in humidified 5% CO2 atmosphere. After that, cells were incubated with 
AMA in order to induce impairment of mitochondrial complex III. Celastrol (purity >98%) was purchased 
from Sigma. Cells were treated with or without celastrol. Untreated cells with dimethyl sulfoxide 
(DMSO) and cells treated with celastrol alone were used as the conditioned controls in this study. Media 
in the controls and treated cells were replaced daily. All experiments were performed in triplicate. 
3.3. Assessment of Cell Viability 
A quantitative colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) (Sigma) were utilized to determine the cell viability. Human myotubes were plated at a density 
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of 1 × 105 cells/well in skeletal muscle growth medium in a 96-well plate. Cells were then treated with 
varying concentration of AMA (10, 30, 50, 100 μM) with or without celastrol (5, 10, 20, 30 μM) in 
DMSO (vehicle). The final concentration of 0.1% DMSO (Sigma) was used. Accordingly, a stock 
concentration of AMA and celastrol was dissolved in DMSO. To ensure the integrity of myotubes 
functions, the optimal dose for each inhibitor that did not significantly affect cell viability was chosen 
for time-course assessment. The time-course evaluation was verified for each optimal dose (12, 24, 36 
and 48 h). Briefly, after indicated treatment, media were removed and washed with PBS. A final 
concentration of 0.5 mg/mL of the MTT solution with the volume of 20 µL was added to each well and 
incubated for 5 h at 37 °C. Then, the MTT solution was removed and 200 μL of dimethyl sulfoxide 
(DMSO) was transferred into each well in order to form blue tetrazolium crystals. The absorbance of the 
final compounds was read at the wavelength of 570 nm and secondary wavelength of 630 nm using a 
ELISA plate reader (Erba LisaScan II, Mannheim, Germany). 
3.4. Glucose Uptake Assay 
To investigate the roles of celastrol in AMA-treated human skeletal muscle cells, glucose uptake 
activity was carried out. The determination of glucose uptake activity rate (µmol/mg/min) in 
differentiated myotubes was performed by quantifying the radio-labeled glucose. Cells were first grown 
in 6-well plates in humidified 5% CO2 at 37 °C. After exposure to 30 µM AMA for 24 h, cells were 
treated with 15 nM celastrol for another 24 h. Then, cells were washed twice with 1 mL/well serum-free 
DMEM for 4 h and immediately incubated with Krebs-Ringer HEPES (KRPH) buffer (118 mM NaCl, 
5 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4 and 30 mM HEPES, pH 7.4) for 30 min. 
For experiments involving insulin stimulation, cells were treated with 100 nM insulin for 30 min at 37 °C. 
Glucose uptake activity was measured by adding 2 µCi of 2-deoxy-D-[3H] glucose and 0.001 mM 
glucose in each well for 10 min at room temperature. After 60 min at 37 °C, cells were washed thrice 
with 3 mL/well of ice cold-PBS solution (pH 7.4) and glucose uptake activity was subsequently 
terminated. Then, cells were incubated and lysed with 0.7 mL of 1% Triton X-100 for 20 min at 37 °C. 
In order to quantify the incorporated radio-labeled glucose, the cell lysates were counted by using  
Tri-Carb 2700TR liquid scintillation counter (Packard Instrument Co., Meriden, CT, USA) [23]. 
3.5. Mitochondrial Superoxide Production 
Human myotubes were plated at 2.5 × 105 cells/well on black 96-well plates. After overnight growth, 
cells were washed with buffer solution. The production of cellular ROS was carried out by staining cells 
with 25 μM 2′,7′-dichlorofluorescin diacetate (DCFDA) (ab113851, Abcam) for 45 min at 37 °C. The 
media were removed and cells were washed two times with PBS. Thereafter, cells were treated with 
AMA with or without celastrol for 48 h. Cells were then collected and measured for fluorescence analysis 
utilizing a multimode plate reader (Promega, Madison, WI, USA) (excitation 485 nm, emission 535 nm). 
3.6. Intracellular ATP Concentration 
Cells were treated with AMA in a 96-well white plate at 37 °C with or without celastrol for 48 h. The 
measurement of total intracellular ATP concentration was measured using a calorimetric ATP Assay Kit 
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32 (KA0806; Abnova Corporation, Walnut, CA, USA). In brief, 100 μL ATP Assay Buffers were used 
to lyse the cells in different wells. The deproteinization of cell lysates was performed by employing a  
10 kDa Spin Column. The intracellular ATP concentration was calculated by comparing an ATP internal 
standard in both treated cells to the ratio of ATP content in untreated cells (control). The relative 
measurement of total intracellular ATP concentration were then measured with ELISA plate reader at 
the wavelength of 570 nm and normalized to protein concentrations. 
3.7. Mitochondrial Membrane Potential (ΔΨm) 
The assessment of mitochondrial membrane potential (MMP) was assayed using the mitochondria-2 
specific lipophilic cationic fluorescence dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-3 
dazolylcarbocyanine iodide (JC-1) Detection Kit (KA1324; Abnova Corporation, Walnut, CA, USA) in 
accordance the manufacturer’s instruction. This assay was performed in order to identify the changes in 
mitochondrial membrane potential relative to mitochondrial functions. Briefly, cells were seeded at  
1 × 106 cells/well in a 96-well black culture plate for 48 h and co-incubated with AMA and celastrol. 
The media were aspirated and cells were washed three times with PBS. After that, 100 µL of JC-1 reagent 
was added into the wells followed by incubation in CO2 incubator at 37 °C for 30 min. The culture plate 
was centrifuged at the speed of 400× g for 5 min and supernatant was removed. The adherent cells were 
then washed twice with PBS and sufficient amount of PBS were added into each well to cover the cell 
layer. Thereafter, 100 μL of Assay Buffer was added to the wells and measured using a multimode plate 
reader (Promega). JC-1 aggregates fluoresced red (excitation 560 nm, emission 595 nm) in healthy cells 
with normal mitochondrial functions and high membrane potentials. In unhealthy cells with diminished 
membrane potential, JC-1 fluoresced green and formed a monomer in mitochondria of the cells. 
3.8. Citrate Synthase Activity 
The mitochondrial citrate synthase activity was quantified in treated human myotubes at an 
immunocapture-based manner using Citrate Synthase Activity Assay Kit (ab119692) (Abcam, 
Cambridge, UK). Briefly, cells were grown in 96-well plate at 2.5 × 105 cells/well and treated with AMA 
before pre-incubation with celastrol. Cells were collected and centrifuged at the speed of 500× g for  
10 min at 4 °C before washed with PBS. Then, cell pellets were solubilized at 2 × 107/mL in extraction 
buffer and incubated on ice for 2 min. Cell pellets were then centrifuged at 16,000× g for 20 min at the 
temperature of 4 °C. Pellets were discarded and supernatant was kept into clean tubes. The quantification 
of the protein in the extracts was performed using PierceTM bicinchonic acid (BCA) protein assay kit 
(Life Technologies, Carlsbad, CA, USA). 100 µL of each diluted supernatant was added into well with 
an addition of a 1× Incubation Buffer as a zero standard. The aliquots were incubated for 3 h at room 
temperature. After incubation, the aliquots were aspirated and washed for two times before dispensing 
with 300 µL 1× Wash buffer into each well. The remaining buffer was removed and plate were inverted 
and blotted against clean paper towel to remove excess liquid. 100 µL of 1× Activity Solution was added 
into each well with minimization of bubble formation. The absorbance was recorded at a wavelength of 
412 nM using an Elisa plate reader. The activity was expressed as µmol/min/mg protein. 
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3.9. Measurement of DNA Oxidative Damage, Protein Carbonylation and Lipid Peroxidation 
Biomarkers of oxidative stress were assayed to measure the oxidative metabolism of the cells. 
Quantification of 8-hydroxydeoxyguanosine (8-OHdG) was determined using the OxiSelectTM 
Oxidative DNA Damage ELISA Kit (Cell Biolabs, San Diego, CA, USA) following the maker’s 
instructions. The relative level of protein carbonylation in cell lysate was measured using a Protein 
Carbonyl Content Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) and lipid peroxidation was 
estimated using Lipid Peroxidation (MDA) Assay Kit (Sigma), as previously described. All assays were 
performed in triplicate and measured calorimetrically using an ELISA plate reader. 
3.10. Cytokine ELISA for IL-6, TNF-α and IL-1β 
Cells were seeded in 96-well white plates in humidified 5% CO2 at 37 °C. The quantitative 
measurement of the relative concentrations of pro-inflammatory cytokines IL-6, TNF-α and IL-1β in 
conditioned media of human myotubes with or without treatment were analyzed using a commercial 
ELISA kit (Invitrogen, Carlsbad, CA, USA), following the user guide provided with the kit. The 
minimum detectable concentration level were 7 pg/mL for IL-1β and 3 pg/mL for both Il-6 and TNF-α. 
The relative concentration of these pro-inflammatory cytokines was obtained from the standard curve 
and expressed as per mg of total extractable cell protein. 
3.11. Western Immunoblotting 
Immunoblotting analysis was carried out as previously reported [23]. Human myotubes were cultured 
on a 6-well plate and serum-starved for 8 h before incubated with AMA and celastrol accordingly for 48 
h. In brief, after treatments, cells were washed twice with ice cold-PBS and Krebs-Ringer HEPES buffer. 
Cells were then homogenized with protein lysis buffer (50 mM Tris pH7.5, 1 mM EDTA, 1 mM EGTA, 
10% glycerol, 1% triton X-100, 50 mM NaF, 5 mM Na4P2O7, 1 mM Na3VO4, 1 mM DTT) containing 
protease and phosphatase inhibitors cocktails (1:1000). After being incubated on ice for 30 min, the 
extraction of total and phosphorylated protein from cell lysates was performed by differential 
centrifugation at the speed of 20,000× g for 20 min at 4 °C. Protein concentration was quantified in 
triplicate using the PierceTM BCA protein assay kit in accordance with the standard protocol provided 
by the supplier (Thermo Scientific, Waltham, Massachusetts, USA). The aliquots of each cell lysate 
(25 μg) were subjected to odecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and directly 
transferred to nitrocellulose membranes (Whatman, London, UK). Following a blocking step in  
Tris-buffered saline/Tween-20 (TBST) containing 5% w/v bovine serum albumin (BSA) for 1 hour at 
room temperature, the membranes were hybridized with the following primary antibodies at 4 °C 
overnight. The secondary antibody was incubated for 1 hour at the same temperature in the dark. The 
membranes and following primary antibodies were diluted overnight in TBST: p-NF-κB p65 (Ser-536) 
(1:1000, Cell Signaling Technology, Danvers, MA, USA), p-IκBα (Ser-32) (1:1000, Cell Signaling 
Technology) FOXO1 (1:1000, Cell Signaling Technology), mfn1 (1:1000, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), mfn2 (1:1000, 32 Santa Cruz Biotechnology), drp1 (1:1000, Santa Cruz 
Biotechnology), pY612-IRS1 (1:1000, Upstate Biotechnology, Lake Placid, NY, USA), IRS1 (1:1000, 
Upstate Biotechnology), pS473-Akt (1:1000, Cell Signaling Technology), Akt (1:1000, Cell Signaling 
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Technology), pS462 AS160 (1:1000, Cell Signaling Technology), AS160 (1:1000, Cell Signaling 
Technology), pPKC θ (1:1000, Santa Cruz), PKC θ (1:1000, Santa Cruz Biotechnology), pAMPK 
(1:1000, Santa Cruz Biotechnology), AMPK (1:1000, Santa Cruz Biotechnology), GLUT4 (1:1000, 35 
Cell Signaling Technology) and β-actin (1:1000, Cell Signaling Technology) at room temperature. The 
blots were then washed with TBST at a dilution of 1:10000 for 1 hour at room temperature before 
incubation with appropriate anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibodies 
(1: 5000) (Life Technologies, Carlsbad, CA, USA). For experiments involving protein phosphorylation, 
cells were stimulated with 100 nM insulin for 10 min, lysed and immuno-precipitated as previously 
described [71]. The blots were developed by chemiluminescence using ECL plus kits (Amersham, 
Piscataway, NJ, USA), visualized using ChemiDocTM XRS + with Image LabTM software. The 
quantification of protein bands was quantified using a standard densitometry. The immunoblotting 
experiments were performed in triplicate. 
3.12. Statistical Analysis 
All experimental data were shown as means ± standard error of the mean (SEM) of the indicated 
sample size (n)—for a minimum of three cell culture experiments. Comparison between groups was 
performed using one-way ANOVA with a Tukey post-hoc test or Duncan’s multiple range tests as 
appropriate; p < 0.05 was considered statistically significant. Analyses were carried out using the SPSS 
16.0 software package. 
4. Conclusions  
In summary, the present study has provided insights into the protective roles of celastrol in 
mitochondrial dysfunction and insulin resistance in human skeletal muscle-derived myoblast. In addition 
to its roles in inhibiting inflammatory signaling, celastrol improved glucose uptake and mitochondrial 
function and enhanced intracellular insulin signaling activities and its downstream targets in AMA-treated 
human skeletal muscle cells. The current study, together with published findings, suggests that celastrol 
is a potential therapeutic molecule for protection against mitochondrial dysfunction and insulin resistance.  
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